Literature DB >> 17927212

Sensitive fluorescence polarization technique for rapid screening of alpha-synuclein oligomerization/fibrillization inhibitors.

Kelvin C Luk1, Edward G Hyde, John Q Trojanowski, Virginia M-Y Lee.   

Abstract

Parkinson's disease (PD) is characterized by the accumulation of fibrillar alpha-synuclein (alpha-Syn) inclusions known as Lewy bodies (LBs) and Lewy neurites. Mutations in the alpha-Syn gene or extra copies thereof cause familial PD or dementia with LBs (DLB) in rare kindreds, but abnormal accumulations of wildtype alpha-Syn also are implicated in the pathogenesis of sporadic PD, the most common movement disorder. Insights into mechanisms underlying alpha-Syn mediated neurodegeneration link alpha-Syn oligomerization and fibrillization to the onset and progression of PD. Thus, inhibiting alpha-Syn oligomer or fibril formation is a compelling target for discovering disease modifying therapies for PD, DLB, and related synucleinopathies. Although amyloid dyes recognize alpha-Syn fibrils, efficient detection of soluble oligomers remains a challenge. Here, we report a novel fluorescence polarization (FP) technique for examining alpha-Syn assembly by monitoring changes in its relative molecular mass during progression of normal alpha-Syn from highly soluble monomers to higher order multimers and thence insoluble amyloid fibrils. We report that FP is more sensitive than conventional amyloid dye methods for the quantification of mature fibrils, and that FP is capable of detecting oligomeric alpha-Syn, allowing for rapid automated screening of potential inhibitors of alpha-Syn oligomerization and fibrillization. Furthermore, FP can be combined with an amyloid dye in a single assay that simultaneously provides two independent biophysical readouts for monitoring alpha-Syn fibrillization. Thus, this FP method holds potential to accelerate discovery of disease modifying therapies for LB PD, DLB, and related neurodegenerative synucleinopathies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17927212     DOI: 10.1021/bi701128c

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  15 in total

1.  Nortriptyline inhibits aggregation and neurotoxicity of alpha-synuclein by enhancing reconfiguration of the monomeric form.

Authors:  Timothy J Collier; Kinshuk R Srivastava; Craig Justman; Tom Grammatopoulous; Birgit Hutter-Paier; Manuela Prokesch; Daniel Havas; Jean-Christophe Rochet; Fang Liu; Kevin Jock; Patrícia de Oliveira; Georgia L Stirtz; Ulf Dettmer; Caryl E Sortwell; Mel B Feany; Peter Lansbury; Lisa Lapidus; Katrina L Paumier
Journal:  Neurobiol Dis       Date:  2017-07-12       Impact factor: 5.996

2.  Fluorescent N-arylaminonaphthalene sulfonate probes for amyloid aggregation of alpha-synuclein.

Authors:  M Soledad Celej; Elizabeth A Jares-Erijman; Thomas M Jovin
Journal:  Biophys J       Date:  2008-03-13       Impact factor: 4.033

3.  Site-Specific Fluorescence Polarization for Studying the Disaggregation of α-Synuclein Fibrils by Small Molecules.

Authors:  Conor M Haney; Christina L Cleveland; Rebecca F Wissner; Lily Owei; Jaclyn Robustelli; Malcolm J Daniels; Merve Canyurt; Priscilla Rodriguez; Harry Ischiropoulos; Tobias Baumgart; E James Petersson
Journal:  Biochemistry       Date:  2016-11-11       Impact factor: 3.162

4.  Identification of aminothienopyridazine inhibitors of tau assembly by quantitative high-throughput screening.

Authors:  Alex Crowe; Wenwei Huang; Carlo Ballatore; Ronald L Johnson; Anne-Marie L Hogan; Ruili Huang; Jennifer Wichterman; Joshua McCoy; Donna Huryn; Douglas S Auld; Amos B Smith; James Inglese; John Q Trojanowski; Christopher P Austin; Kurt R Brunden; Virginia M-Y Lee
Journal:  Biochemistry       Date:  2009-08-18       Impact factor: 3.162

5.  Interactions between Soluble Species of β-Amyloid and α-Synuclein Promote Oligomerization while Inhibiting Fibrillization.

Authors:  Jason Candreva; Edward Chau; Margaret E Rice; Jin Ryoun Kim
Journal:  Biochemistry       Date:  2019-12-30       Impact factor: 3.162

6.  Native chemical ligation of thioamide-containing peptides: development and application to the synthesis of labeled α-synuclein for misfolding studies.

Authors:  Solongo Batjargal; Yanxin J Wang; Jacob M Goldberg; Rebecca F Wissner; E James Petersson
Journal:  J Am Chem Soc       Date:  2012-04-02       Impact factor: 15.419

7.  Baicalein reduces E46K alpha-synuclein aggregation in vitro and protects cells against E46K alpha-synuclein toxicity in cell models of familiar Parkinsonism.

Authors:  Mali Jiang; Yair Porat-Shliom; Zhong Pei; Yong Cheng; Lan Xiang; Katherine Sommers; Qing Li; Frank Gillardon; Bastian Hengerer; Cynthia Berlinicke; Wanli W Smith; Donald J Zack; Michelle A Poirier; Christopher A Ross; Wenzhen Duan
Journal:  J Neurochem       Date:  2010-04-19       Impact factor: 5.372

8.  Interactions between Hsp70 and the hydrophobic core of alpha-synuclein inhibit fibril assembly.

Authors:  Kelvin C Luk; Ian P Mills; John Q Trojanowski; Virginia M-Y Lee
Journal:  Biochemistry       Date:  2008-11-25       Impact factor: 3.162

9.  α-synuclein-assisted oligomerization of β-amyloid (1-42).

Authors:  Edward Chau; Jin Ryoun Kim
Journal:  Arch Biochem Biophys       Date:  2022-01-15       Impact factor: 4.013

10.  Covalent α-synuclein dimers: chemico-physical and aggregation properties.

Authors:  Micaela Pivato; Giorgia De Franceschi; Laura Tosatto; Erica Frare; Dhruv Kumar; Daniel Aioanei; Marco Brucale; Isabella Tessari; Marco Bisaglia; Bruno Samori; Patrizia Polverino de Laureto; Luigi Bubacco
Journal:  PLoS One       Date:  2012-12-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.